HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.

PubWeight™: 1.27‹?› | Rank: Top 10%

🔗 View Article (PMID 25217962)

Published in Nat Genet on September 14, 2014

Authors

Graham A Heap1, Michael N Weedon2, Claire M Bewshea3, Abhey Singh4, Mian Chen5, Jack B Satchwell5, Julian P Vivian6, Kenji So4, Patrick C Dubois7, Jane M Andrews8, Vito Annese9, Peter Bampton10, Martin Barnardo5, Sally Bell11, Andy Cole12, Susan J Connor13, Tom Creed14, Fraser R Cummings15, Mauro D'Amato16, Tawfique K Daneshmend4, Richard N Fedorak17, Timothy H Florin18, Daniel R Gaya19, Emma Greig20, Jonas Halfvarson21, Alisa Hart22, Peter M Irving23, Gareth Jones24, Amir Karban25, Ian C Lawrance26, James C Lee27, Charlie Lees24, Raffi Lev-Tzion28, James O Lindsay29, John Mansfield30, Joel Mawdsley31, Zia Mazhar32, Miles Parkes27, Kirstie Parnell33, Timothy R Orchard34, Graham Radford-Smith35, Richard K Russell36, David Reffitt37, Jack Satsangi24, Mark S Silverberg38, Giacomo C Sturniolo39, Mark Tremelling40, Epameinondas V Tsianos41, David A van Heel42, Alissa Walsh43, Gill Watermeyer44, Rinse K Weersma45, Sebastian Zeissig46, Jamie Rossjohn6, Arthur L Holden47, International Serious Adverse Events Consortium, IBD Pharmacogenetics Study Group, Tariq Ahmad3

Author Affiliations

1: 1] IBD Pharmacogenetics, Royal Devon and Exeter Hospital, Exeter, UK. [2] Precision Medicine Exeter, University of Exeter, Exeter, UK. [3].
2: 1] Precision Medicine Exeter, University of Exeter, Exeter, UK. [2].
3: 1] IBD Pharmacogenetics, Royal Devon and Exeter Hospital, Exeter, UK. [2] Precision Medicine Exeter, University of Exeter, Exeter, UK.
4: IBD Pharmacogenetics, Royal Devon and Exeter Hospital, Exeter, UK.
5: Oxford Transplant Centre, Oxford University Hospital National Health Service (NHS) Trust, Oxford, UK.
6: Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.
7: Department of Gastroenterology, King's College Hospital, London, UK.
8: IBD Service, Department of Gastroenterology and University of Adelaide at Royal Adelaide Hospital, Adelaide, South Australia, Australia.
9: Division of Gastroenterology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
10: Flinders Medical Centre, Flinders University of South Australia, Adelaide, South Australia, Australia.
11: Department of Gastroenterology, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
12: Gastroenterology and Hepatology, Royal Derby Hospital, Derby, UK.
13: Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, New South Wales, Australia.
14: Joint Clinical Research Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
15: Department of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
16: Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden.
17: Division of Gastroenterology, University of Alberta, Edmonton, Alberta, Canada.
18: The University of Queensland School of Medicine, South Brisbane, Queensland, Australia.
19: Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, UK.
20: Department of Gastroenterology, Taunton and Somerset NHS Foundation Trust, Taunton, UK.
21: Division of Gastroenterology, Örebro University Hospital and School of Health and Medical Sciences, Örebro University, Örebro, Sweden.
22: Department of Medicine, St. Mark's Hospital and Academic Institute, North West London Hospitals NHS Trust, London, UK.
23: Department of Gastroenterology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
24: Department of Gastroenterology, Western General Hospital, Edinburgh, UK.
25: Department of Gastroenterology, Rambam Medical Center, Haifa, Israel.
26: Centre for Inflammatory Bowel Diseases, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia.
27: Department of Gastroenterology, Cambridge University Hospitals NHS Trust, Cambridge, UK.
28: Paediatric Gastroenterology and Nutrition Unit, Shaare Zedek Medical Centre, Jerusalem, Israel.
29: Department of Gastroenterology, Barts and The London NHS Trust, London, UK.
30: Department of Gastroenterology, Newcastle University Hospitals NHS Trust, Newcastle, UK.
31: Department of Gastroenterology, West Middlesex University Hospital NHS Trust, Isleworth, UK.
32: Department of Gastroenterology, Basildon and Thurrock Hospital NHS Trust, Basildon, UK.
33: Precision Medicine Exeter, University of Exeter, Exeter, UK.
34: Department of Medicine, Imperial College Healthcare NHS, London, UK.
35: 1] Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. [2] IBD Group, Queensland Institute of Medical Research and University of Queensland School of Medicine, Herston Campus, Brisbane, Queensland, Australia.
36: Department of Paediatric Gastroenterology, Yorkhill Hospital, Glasgow, UK.
37: Department of Gastroenterology, Lewisham and Greenwich NHS Trust, London, UK.
38: Inflammatory Bowel Disease Group, Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, Ontario, Canada.
39: Gastroenterologia, Univerita di Padova, Padova, Italy.
40: Department of Gastroenterology, Norfolk and Norwich Hospital NHS Trust, Norwich, UK.
41: 1st Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
42: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
43: Department of Gastroenterology, St. Vincent's Hospital, Sydney, New South Wales, Australia.
44: Gastrointestinal Clinic, Groote Schuur Hospital, Cape Town, South Africa.
45: Department of Gastroenterology and Hepatology, University Medical Center Groningen and the University of Groningen, Groningen, the Netherlands.
46: Department of Internal Medicine, University Medical Center Schleswig-Holstein, Kiel, Germany.
47: The International Serious Adverse Events Consortium, Chicago, Illinois, USA.

Articles citing this

Genetics of Inflammatory Bowel Diseases. Gastroenterology (2015) 1.11

Toxic-metabolic Risk Factors in Pediatric Pancreatitis: Recommendations for Diagnosis, Management, and Future Research. J Pediatr Gastroenterol Nutr (2016) 0.90

NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J (2015) 0.90

Pathogenesis of Crohn's disease. F1000Prime Rep (2015) 0.81

Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol (2016) 0.79

Biomarkers in Search of Precision Medicine in IBD. Am J Gastroenterol (2016) 0.79

10 Years of GWAS Discovery: Biology, Function, and Translation. Am J Hum Genet (2017) 0.78

Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. PLoS One (2017) 0.77

Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis. PLoS One (2015) 0.77

Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clin Pharmacokinet (2016) 0.77

Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. Expert Rev Clin Immunol (2016) 0.76

Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Sci Rep (2016) 0.75

Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases-A Prospective Study on Incidence and Severity. J Crohns Colitis (2015) 0.75

New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. J Allergy Clin Immunol (2015) 0.75

Digesting GWAS. Cell Mol Gastroenterol Hepatol (2016) 0.75

Pharmacogenomics of off-target adverse drug reactions. Br J Clin Pharmacol (2017) 0.75

Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75

Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. Pharmgenomics Pers Med (2017) 0.75

Thioguanine in inflammatory bowel disease: Long-term efficacy and safety. United European Gastroenterol J (2016) 0.75

More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. Inflamm Bowel Dis (2017) 0.75

Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut (2017) 0.75

Articles cited by this

PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95

A map of human genome variation from population-scale sequencing. Nature (2010) 121.13

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20

MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol (2010) 26.41

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem (2010) 25.20

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem (2009) 23.19

GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet (2010) 20.73

Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet (2012) 11.29

HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98

BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques (2002) 5.98

Robust relationship inference in genome-wide association studies. Bioinformatics (2010) 5.57

Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet (2009) 4.61

The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45

Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol (2007) 3.36

Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One (2013) 3.07

Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature (2012) 2.46

Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17

Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics (2004) 2.04

zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics (2012) 1.87

Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2009) 1.74

A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med (2013) 1.69

HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol (2011) 1.60

Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One (2011) 1.45

Acute pancreatitis as a complication of Imuran therapy in regional enteritis. Gastroenterology (1972) 1.39

Retraction. Science (2011) 1.32

Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis (2013) 1.31

Converting an odds ratio to a range of plausible relative risks for better communication of research findings. BMJ (2014) 1.28

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (2012) 1.25

Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf (2004) 1.17

Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol (2012) 1.10

Hemorrhagic pancreatitis. A fatal complication of renal transplantation. N Engl J Med (1966) 1.00

Articles by these authors

Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut (2014) 2.36

Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol (2014) 1.23

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21

Probiotics and prebiotics in gastrointestinal disorders. Curr Opin Gastroenterol (2004) 1.09

Fine mapping in the MHC region accounts for 18% additional genetic risk for celiac disease. Nat Genet (2015) 1.09

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology (2016) 1.02

Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. Clin Transl Gastroenterol (2014) 1.01

Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. J Hepatol (2014) 0.91

NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease. Am J Gastroenterol (2004) 0.89

Paneth cell marker CD24 in NOD2 knockout organoids and in inflammatory bowel disease (IBD). Gut (2013) 0.82

A Systematic Review for the Development of a Core Outcome Set for Ulcerative Colitis Clinical Trials. Clin Gastroenterol Hepatol (2017) 0.75

Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open (2017) 0.75

Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study. Frontline Gastroenterol (2014) 0.75

Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. Dig Liver Dis (2016) 0.75

Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. Gastroenterology (2015) 0.75

The organisation and structure of inflammatory bowel disease services for children and young people in the UK in 2010: significant progress but still room for improvement. Frontline Gastroenterol (2012) 0.75